Locate healthcare providers and researchers who have knowledge of your condition.
Navigate the process of trying to obtain a diagnosis.
Research Funding Resources
Explore this section to find information on research funding opportunities from the National Institutes of Health and other sources
The National Health Council just announced the availability of a database that will help link unfunded NIH applications with potential nongovernmental funding sources.
NIH medical and behavioral research grant policies, guidelines, and funding opportunities including the NIH Guide for Grants and Contracts.
A searchable database of federally funded biomedical research projects conducted at universities, hospitals, and research institutions.
A single governmentwide source for information about grants programs across the Federal government.
The Center for Scientific Review (CSR) is the portal for NIH grant applications and their review for scientific merit. We organize the peer review groups or study sections that evaluate the majority (70%) of the research grant applications sent to NIH. We also receive all grant applications for NIH, as well as for some other components of the U.S. Department of Health and Human Services (DHHS). Since 1946, our mission has remained clear and timely: to see that NIH grant applications receive fair, independent, expert, and timely reviews -- free from inappropriate influences -- so NIH can fund the most promising research.
Resources available through the Small Business Innovation Research and the Small Business Technology Transfer programs.
NORD's Research Program provides seed money grants to academic scientists for clinical studies related to the development of diagnostics or treatments of rare diseases. Requests for proposals are posted once a year in the late winter or early spring. NORD's Research Program also includes the NORD/Roscoe Brady Lysosomal Storage Diseases Fellowships.Back to top
Conquering the Histiocytic Disorders 2013 Request for Research Proposals The Histiocytosis Association funded more than $300,000 in scientific research in 2012. Application for 2013 funding will be accepted online from May 15 to July 31, 2013.
The mission of the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension (PAH) is to support innovative scientific research that will advance knowledge in the field of pulmonary arterial hypertension, or PAH. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of pulmonary arterial hypertension.
2014 Bachmann-Strauss RFP The application can also be found on The Bachmann-Strauss Foundation website(www.dystonia-parkinson.org) The deadline date for Grant Applications is Friday, September 13, 2013.
The Center for Orphan Disease Research and Therapy announces a Request for Applications (RFA) to support research on the development of improved therapies for patients with syndromes due to MPS I including Hurler, Hurler-Scheie and Scheie. Particular emphasis will be on treatments that improve aspects of the disease which are not adequately treated by enzyme replacement therapy such as pathology in the CNS, skeletal system, eye and heart among others.
The NBIA Disorders Association is accepting applications for one-year grants for clinical and translational research studies related to the early detection, diagnosis, or treatment of patients with NBIA. Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare, genetic, neurological disorders characterized by the accumulation of iron deposits in the brain and progressive degeneration of the nervous system. It typically first appears in childhood. Presenting signs and symptoms may include difficulty walking, loss of balance, and problems related to speech. Those affected suffer a progressive loss of muscle control, sudden involuntary muscle spasms, and uncontrolled tightening of the muscles. Symptoms may also include disorientation, seizures, and deterioration of intellectual ability. Approximately half of the cases diagnosed have been linked to a mutation of a gene known as PANK2. At the present time, symptoms for the disorders may be treated but there is no cure.
The Histiocytosis Association of America’s Research Program seeks to attain its goal of a cure through a variety of efforts, the foremost being the direct funding of both basic and clinical scientific research projects. Through the annual Research Grant Awards, the Association supports basic scientific research into understanding the function of cells and the disease process.
Beginning January 4, the 2010 Request for Proposals will be available on the Association’s website at www.histio.org/requestforproposals. Information regarding the application deadline, notification of awarded grants, and maximum funding request can be found on this page as well. Researchers considering applying to the Association’s research grant program are encouraged to direct any questions to the Association at email@example.com, or by phone at 1 800-548-2758 (toll-free in the United States and Canada only) or 856-589-6606.
MDA's research program is a dedicated partnership between scientists and concerned citizens aimed at conquering neuromuscular disease. MDA combats some 40 neuromuscular diseases through a worldwide extramural research program that includes basic, clinical, and translational research efforts as well as a clinical research training grant program. MDA's focus is not simply to fund good science but to fund good science aimed at developing treatments and therapies for neuromuscular disease.
The National Ataxia Foundation funds four types of research grants for new and innovative studies that are relevant to the cause, pathogenesis, or treatment of the hereditary or sporadic ataxias.
The National Marfan Foundation (NMF) is proud to announce the 2011 Victor A. McKusick Fellowship Program. Two-year fellowship awards are available for Ph.D.s for up to $50,000 per year and M.D.s up to $75,000 per year. Fellows up to postgraduate year 6 will be considered. This program is designed to cultivate promising young physician scientists or research scientists conducting basic, translational, or clinical research in the field of Marfan syndrome and related disorders. This award is being given to stimulate the advancement toward independent research in the field of Marfan syndrome. During the fellowship phase, the applicant will be required to work with a mentor who can provide a training environment conducive to beginning a career in any of the disciplines related to Marfan research such as cardiovascular, orthopedic, ophthalmologic, pulmonary, and genetics. Fellowship awards will be given based on proposal evaluations by the NMF Scientific Advisory Board with the approval of the NMF Board of Directors. No overhead or indirect costs will be considered. Proposals must be prepared according to NMF guidelines.
The National Marfan Foundation grant program for researchers with faculty appointments is designed to provide financial support for investigators studying any or all disciplines involved in the Marfan syndrome. Special areas of interest include cardiovascular, genetic, orthopedic and ophthalmologic issues of the Marfan syndrome and related disorders. The National Marfan Foundation accepts applications on a yearly basis for 1- or 2-year grants in basic, translational, or clinical research. Applications with budgets up to $50,000 per year for a total of $100,000 are acceptable. Grant awards are based on peer review by the NMF Scientific Advisory Board with the approval of the NMF Board of Directors.
The NephCure Foundation is the only organization devoted exclusively to supporting research into the cause of and cure for Idiopathic Nephrotic Syndrome and primary Focal Segmental Glomerulosclerosis (FSGS). Comprised of patients, their families and friends, researchers, physicians, and other health care professionals, NephCure has a growing program of scientific support.
The Aplastic Anemia MDS International Foundation offers 2-year research grants of $30,000 per year to advance the understanding and treatment of bone marrow failure diseases, including aplastic anemia, myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH).The research grant program application and guidelines are available at the MDSIF Web site.
Awards of up to $50,000 per year for up to 2 years are available from PRF to support investigators for basic science research aimed at developing effective treatments and/or a cure for Hutchinson-Gilford Progeria Syndrome and its aging-related disorders. Principal investigators must hold postdoctoral positions or beyond. Awards will be granted only to applicants affiliated with institutions with 501(c)3 status or the equivalent for foreign institutions.
The UMDF promotes research and education for the diagnosis, treatment, and cure of mitochondrial disorders and provides support to affected individuals and families. Through its Research Program, UMDF awards more than $1 million per year in grants to scientists conducting basic research into mitochondrial disorders as well as for clinical studies focusing on diagnosis and treatment.
The purpose of the Vasculitis Foundation Research Grant Program is to provide 1- or 2-year seed grants to support pilot studies in researching the etiology; epidemiology; diagnosis; treatment; including approaches that would prevent complications; and development of coping skills for living with this disease.Back to top
The CTSA program in the NCATS Division of Clinical Innovation supports a national consortium of medical research institutions that work together to improve the way clinical and translational research is conducted nationwide to enhance its efficiency and quality.
The goal of the NIH Chemical Genomics Center's Assay Biology Teams in the NCATS Division of Pre-Clinical Innovation is to optimize biochemical, cellular and model organism-based assays requested or submitted by the biomedical research community for high-throughput small molecule screening.
BrIDGs makes available, on a competitive basis, certain critical resources needed for the development of new therapeutic agents.
NIH Chemical Genomics Center's Chemistry Technology Group in the NCATS Division of Pre-Clinical Innovation aims to solve fundamental problems and insufficiencies in molecular biology and drug discovery through investments in chemistry technology projects ranging from novel library design to inventive bioanalytical techniques.
The NIH Chemical Genomics Center is one of the centers in the Molecular Libraries Probe Production Centers Network (MLPCN), which is an NIH Common Fund Initiative.
The goals of NCGC in the NCATS Division of Pre-Clinical Innovation are to translate the discoveries of the Human Genome Project into biological and disease insights and ultimately new therapeutics for human disease through small molecule assay development, high-throughput screening, cheminformatics and chemistry.
NIH established a state-of-the-art RNAi screening facility administered by the NCATS Division of Pre-Clinical Innovation that accepts proposals from any intramural researcher.
The TRND program in the NCATS Division of Pre-Clinical Innovation aims to encourage and speed the development of new drugs for rare and neglected diseases.
The Tox21 program is a federal collaboration involving the NIH, Environmental Protection Agency (EPA), and Food and Drug Administration (FDA) aimed at developing better toxicity assessment methods.
The Tissue Chip for Drug Screening initiative, which marks the first interagency collaboration launched by NCATS, aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart.
This collaborative pilot program is designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutic development.Back to top
Learn more about the funding and collaboration opportunities that NCATS offers.
NCATS seeks to increase small business participation in federally supported research and development as well as private-sector commercialization of technology developed with federal support.Back to top